COMMUNIQUÉS West-GlobeNewswire

TESARO Announces Third-Quarter 2018 Operating Results

01/11/2018 - 21:05

ZEJULA® Q3 net sales totaled $63 million compared to $39 million for Q3 2017 Top-line results for PRIMA trial of ZEJULA monotherapy for first-line ovarian cancer patients regardless of BRCA mutation status anticipated [...]

Novavax Appoints Rachel King to Board of Directors

01/11/2018 - 21:05

GAITHERSBURG, Md., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq: NVAX) today announced the appointment of Rachel King, Co-Founder and Chief Executive Officer of GlycoMimetics, Inc., to its Board of Directors [...]

IRIDEX Announces 2018 Third Quarter Financial Results and Raises Full Year 2018 Guidance

01/11/2018 - 21:05

MOUNTAIN VIEW, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter and nine months ended September 29, 2018. Third Quarter Highlights Cyclo [...]

Geron Corporation Reports Third Quarter 2018 Financial Results and Recent Company Events

01/11/2018 - 21:05

Imetelstat program transition proceeding, including plans to initiate Phase 3 portion of IMerge Abstracts for IMbark and IMerge accepted for oral presentation at American Society of Hematology Meeting (ASH) in December [...]

Conatus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Program Updates

01/11/2018 - 21:05

SAN DIEGO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today [...]

Helius Medical Technologies to Present at the 12th Annual Canaccord Medical Technologies & Diagnostics Forum

01/11/2018 - 21:05

NEWTOWN, Pa., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that [...]

Portola Pharmaceuticals to Present New Interim Phase 2 Results for Cerdulatinib During an Oral Session at the 60th American Society of Hematology (ASH) Annual Meeting

01/11/2018 - 21:03

– Differentiated Syk/JAK Inhibitor Studied in Patients with Heavily Pre-Treated T-Cell Malignancies – – Also Accepted: Two Posters on Andexxa ® and an Oral Session on the Burden of Hospital Readmissions Due to Venous [...]

NewLink Genetics Reports Third Quarter 2018 Financial Results and Announces Abstracts to Be Presented at Upcoming Medical Meetings

01/11/2018 - 21:01

Management to Host Conference Call Today at 4:30 p.m. ET AMES, Iowa, Nov. 01, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today reported consolidated financial results for the third quarter 2018 [...]

Tetraphase Pharmaceuticals to Host Third Quarter 2018 Financial Results Conference Call

01/11/2018 - 21:01

WATERTOWN, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening [...]

T2 Biosystems Reports Third Quarter 2018 Financial Results and Provides Corporate Update

01/11/2018 - 21:01

Quarterly Product Revenue Up 71% Year-Over-Year Reiterates 2018 Financial Guidance LEXINGTON, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization [...]

Allscripts announces third quarter 2018 results

01/11/2018 - 21:01

Reported third quarter growth of 16% in GAAP revenue to $522 million, 19% in non-GAAP revenue to $536 million Third quarter GAAP loss per share of $0.20, growth of 13% in non-GAAP EPS to $0.18 Year-to-date growth of 21 [...]

athenahealth Announces New Time For Third Quarter 2018 Earnings Release and Conference Call

01/11/2018 - 21:01

WATERTOWN, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- athenahealth, Inc. (NASDAQ: ATHN), a leading provider of network-enabled services for hospital and ambulatory clients nationwide, today announced that its third [...]

Retrophin Reports Third Quarter 2018 Financial Results

01/11/2018 - 21:01

Pivotal programs enrolling towards first data readout in 2019 Phase 2 study of CNSA-001 in PKU underway; top-line results expected in first half 2019 Completed offering of $276 million convertible senior notes due 2025 [...]

Adamas Reports Third Quarter 2018 Financial Results

01/11/2018 - 21:01

GOCOVRI™ (amantadine) extended release capsules sales increased to $10.6 million for the third quarter, with ~4,740 fulfilled prescriptions EMERYVILLE, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, [...]

Align Technology SVP Chris Puco to Depart in March 2019

01/11/2018 - 21:00

SAN JOSE, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Align Technology, Inc. (Nasdaq: ALGN) today announced that Christopher C. Puco, senior vice president and managing director of the Americas region, has decided to [...]

IntelGenx to Report Third Quarter 2018 Financial Results on November 8, 2018 – Conference Call to Follow

01/11/2018 - 21:00

SAINT LAURENT, Quebec, Nov. 01, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX VENTURE:IGX) (OTCQX:IGXT) today announced that it will release its third quarter 2018 financial results after market close on [...]

Cytokinetics, Inc. Reports Third Quarter 2018 Financial Results

01/11/2018 - 21:00

METEORIC-HF Advancing to Trial Initiation FORTITUDE-ALS on Track to Complete Enrollment by Year End Phase 1 Clinical Studies of CK-274 and AMG 594 To Start in Q4 SOUTH SAN FRANCISCO, Calif., Nov. 01, 2018 (GLOBE [...]

Weekend Unlimited: Emerging Cannabis Lifestyle Brand -- CFN Media

01/11/2018 - 18:05

SEATTLE, Nov. 01, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering [...]

Holding(s) in Company

01/11/2018 - 17:34

TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the [...]